Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | PYGB | P11216 | 1/20 | 0.36 |
| ▸ | FGF1 | P05230 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13482776 | 1.00 | LGALS8 (0.43) | LGALS8L3MBTL1MAPTCD209GAA | |
| SCHEMBL20033536 | 1.00 | LGALS8 (0.43) | LGALS8L3MBTL1MAPTCD209GAA | |
| SCHEMBL17256295 | 1.00 | LGALS8 (0.43) | LGALS8L3MBTL1MAPTCD209GAA | |
| SCHEMBL13483316 | 1.00 | LGALS8 (0.43) | LGALS8L3MBTL1MAPTCD209GAA | |
| SCHEMBL14864297 | 1.00 | LGALS8 (0.43) | LGALS8L3MBTL1MAPTCD209GAA | |
| SCHEMBL23723836 | 1.00 | LGALS8 (0.43) | LGALS8L3MBTL1MAPTCD209GAA | |
| SCHEMBL16504207 | 1.00 | LGALS8 (0.43) | LGALS8L3MBTL1MAPTCD209GAA | |
| SCHEMBL17154136 | 0.88 | LGALS8 (0.39) | LGALS8L3MBTL1MAPTCD209OGA | |
| SCHEMBL14802349 | 0.88 | LGALS8 (0.39) | LGALS8L3MBTL1MAPTCD209OGA | |
| SCHEMBL15293443 | 0.88 | LGALS8 (0.39) | LGALS8L3MBTL1MAPTCD209OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | YALE UNIVERSITY (US) | 2023-09-26 | — | — | US | disclosed |
| WO-2023178179-A2 | BI-FUNCTIONAL MOLECULES TO DEGRADE CIRCULATING PROTEINS | YALE UNIVERSITY (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023178202-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | YALE UNIVERSITY (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2022035997-A1 | IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS | AVILAR THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20210145974-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | YALE UNIVERSITY | 2021-05-20 | — | — | US | disclosed |
| US-20210139436-A1 | Bi-functional Molecules to Degrade Circulating Proteins | YALE UNIVERSITY | 2021-05-13 | — | — | US | disclosed |
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | PFIZER INC. (US) | 2020-12-01 | — | — | US | disclosed |
| EP-3145934-B1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10813942-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20190321382-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2019-10-24 | — | — | US | disclosed |
| WO-2019199634-A1 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | YALE UNIVERSITY (US) | 2019-10-17 | — | — | WO | disclosed |
| US-10376531-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10039778-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170165284-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-9617293-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2017-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | LGALS8 87/4885L3MBTL1 2804/4885MAPT 4521/4885 |
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | MIF, ASGR1, FCGR2A | LGALS8 106/4885L3MBTL1 2031/4885MAPT 4321/4885 |
| US-20170165284-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | ASGR1, MRGPRX2, LDLR | LGALS8 51/4885L3MBTL1 4432/4885MAPT 4003/4885 |
| US-10813942-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | ASGR1, MRGPRX2, LDLR | LGALS8 51/4885L3MBTL1 4432/4885MAPT 4003/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | LGALS8 258/4885L3MBTL1 1095/4885MAPT 4775/4885 |
| US-20210145974-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR3B | LGALS8 347/4885L3MBTL1 1302/4885MAPT 4514/4885 |
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | ASGR1, LDLR, HAVCR2 | LGALS8 71/4885L3MBTL1 468/4885MAPT 3945/4885 |
| US-20190321382-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | ASGR1, MRGPRX2, LDLR | LGALS8 51/4885L3MBTL1 4432/4885MAPT 4003/4885 |
| US-10039778-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | ASGR1, MRGPRX2, LDLR | LGALS8 51/4885L3MBTL1 4432/4885MAPT 4003/4885 |
| US-20210139436-A1 | Bi-functional Molecules to Degrade Circulating Proteins | MIF, ASGR1, FCGR2A | LGALS8 106/4885L3MBTL1 2031/4885MAPT 4321/4885 |
| US-10376531-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | ASGR1, MRGPRX2, LDLR | LGALS8 51/4885L3MBTL1 4432/4885MAPT 4003/4885 |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | LGALS8 77/4885L3MBTL1 2462/4885MAPT 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.